“We found that the addition of SBRT for patients who are on immunotherapy to be safe and well-tolerated, meaning that radiation oncologists can feel confident continuing immunotherapy for most patients when adding SBRT to lung or liver metastases. In fact, there may be additional benefit from combining the therapies in terms of improved disease control. Follow-up research in larger clinical trials is needed to determine which types of tumors and patients will respond best to this immunotherapy-radiation approach,” said Dr. Welsh.
“For the best care now, there is more than one right way to go,” she continued. “Radiation oncologists around the world will differ in their recommendations. Generally, for women with four or more positive lymph nodes, radiation to the supraclavicular lymph nodes often is recommended. And, if the cancer is in the central to inner area of the breast, then radiation also may be recommended to the internal mammary lymph nodes. For women who have one to three positive nodes, the role of radiation is more likely to fall into a grey zone.”